The Clinical Benefit of Ruxolitinib Across Patient Subgroups: Analysis of a Placebo-Controlled, Phase III Study in Patients With Myelofibrosis
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.12274
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 11, 2013
Authors
Publisher
Wiley